Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program

OBJECTIVE: Patients with lipodystrophy have severe metabolic abnormalities (insulin resistance, diabetes, and hypertriglyceridemia) that may increase morbidity and mortality. Metreleptin is approved by the United States Food and Drug Administration for treatment of generalized forms of lipodystrophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajluni, Nevin, Dar, Moahad, Xu, John, Neidert, Adam H, Oral, Elif A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026130/
https://www.ncbi.nlm.nih.gov/pubmed/27642538
http://dx.doi.org/10.4172/2155-6156.1000659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026130/
https://www.ncbi.nlm.nih.gov/pubmed/27642538
http://dx.doi.org/10.4172/2155-6156.1000659

Ejemplares similares